Magenta therapeutics announces commencement of first phase 2 clinical trial of mgta-145 for stem cell mobilization, oral presentation of mgta-145 phase 1 results and update on targeted adc conditioning program mgta-117 at ash annual meeting

Cambridge, mass.--(business wire)--magenta therapeutics (nasdaq: mgta), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today announced final clinical results from its earlier completed phase 1 clinical trial as well as development updates for its mgta-145 stem cell mobilization therapy, including commencement of enrollment in a phase 2 clinical trial in multiple myeloma, and its plans for a phase 2 clinical
DNTH Ratings Summary
DNTH Quant Ranking